Skip to navigation Skip to content

Commercial R&D Funding Portfolio


Commercial R&D Funding Portfolio

A selected list of National MS Society commercial funding projects according to research area are shown below.

Neuroprotection and Repair
New York University; Gli1
University College London; potassium channel modulator
Karyopharm Therapeutics; KPT-350
Centre for Mental Health and Addiction; GluR2/GAPDH
Bionure; BN201
Therini Bio; 5B8 mAb
Brigham and Women’s Hospital; etifoxine analogs
Cashel Neural; remyelination
University of California, Riverside; ERβ , remyelination

Modulating the Immune Response
Amplimmune; AMP110
Apitope; ATX-MS-1467
TG Therapeutics; TGR-1202

Stem-cell based therapeutics
Athersys; MultiStem

Diagnostics and Biomarkers
GE Healthcare; GE-180
DioGenix; MSPrecise
Clene Nanomedicine Inc.
BrainStorm, MSC-NTF cells

Symptoms Management
Canbex Therapeutics, VSN16R
Accera / University of Miami; Axona
Concert Pharmaceuticals; CTP-354

View a comprehensive list of all Fast Forward funded projects


Bike MS: Inside Out

Live Broadcast on Sept. 26 at 10 a.m.​ ET

Register or Donate Now
© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.